Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic combination therapy as a tumor‐selective treatment approach for hepatocellular carcinoma

3 Apr 2007

Abstract excerpt

BACKGROUND: Innovative epigenetic therapeutics comprise histone deacetylase inhibitors (HDAC-I) and demethylating agents (DA). It was recently found that HDAC-I compounds exhibit profound therapeutic activities against hepatocellular carcinoma (HCC). A comprehensive preclinical investigation was performed on the potential of a combined HDAC-I/DA epigenetic regimen for the highly chemotherapy-resistant HCC entity....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Hepatocellular Carcinoma Treatment and Prognosis
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17407132
DOI: 10.1002/cncr.22652

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic combination therapy as a tumor‐selective treatment approach for hepatocellular carcinomaPMID 17407132Read ↗

The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatmentSemantic proximity Read ↗

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.Semantic proximity Read ↗

Histone-Deacetylase Inhibitors for the Treatment of CancerSemantic proximity Read ↗

Histone Deacetylase Inhibitors: Development of Suberoylanilide Hydroxamic Acid (SAHA) for the Treatment of CancersSemantic proximity Read ↗

Histone deacetylase inhibitors in cancer therapy. A reviewSemantic proximity Read ↗

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.Semantic proximity Read ↗

A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with ImmunotherapySemantic proximity Read ↗

Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer.Semantic proximity Read ↗

Radiosensitizing Potential of Epigenetic Anticancer DrugsSemantic proximity Read ↗

The Pharmaceutical Potential of Histone Deacetylase InhibitorsSemantic proximity Read ↗

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylasesSemantic proximity Read ↗

Unique Combinations of epigenetic modifiers synergistically impair the viability of the U87 glioblastoma cell line while exhibiting minor or moderate effects on normal stem cell growthSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.